94 results about "Lysophospholipids" patented technology

The present invention is an enzymatic method and diagnostic kits for detecting and quantifying the presence of one or more lysophospholids in a sample of bodily fluid taken from a test subject. The method uses enzymes in a two step assay and may be used to detect disease conditions associated with altered levels of lysophospholipids and to correlate such conditions with altered levels of lysophospholipids.

A method of using a bioactive lysophospholipid (LL) as a biomarker for detecting the presence and recurrence of ovarian cancer. Subspecies of LL, such as lysophosphatidic acid (LPA), lysophosphatidylinositol (LPI), lysophosphatidylcholine (LPC), and lysosphingolipid sphinsosine-1-phosphate (S1P), are used alone or in conjunction to increase the specificity and sensitivity of the assay.

The present invention provides a method for preparing a solubilized composition containing an oil-soluble substance having both acid and heat resistance, including:

the step of dissolving an oil-soluble substance and two or three emulsifiers selected from

(1) an emulsifier E1 comprising an ester of a fatty acid having an HLB of not less than 10 and not more than 14 carbon atoms with a polyglycerol having a polymerization degree of not less than 3,

(2) an emulsifier E2 comprising an ester of a fatty acid having an HLB of not less than 10 and not more than 14 carbon atoms with sucrose, or

(3) an emulsifier E3 comprising lecithin in which phosphatidylcholine accounts for not less than 50% and/or lysolecithin in which lysophosphatidylcholine accounts for not less than 50% of a phospholipid content in (a) ethanol or (b) a mixed solvent of ethanol with at least one selected from the group consisting of acetone, hexane, and ethyl acetate to prepare a transparent solution; and

the step of distilling the solvent off from the transparent solution.

Lipophilic compounds extracted from cell growth mediums, particularly lysophospholipids are used to solubilize single-walled nanotubes. The naturally occurring lysophospholipids were found to readily bond to the exterior wall of the single-walled nanotubes to enhance the biocompatibility of the single-walled nanotubes in therapeutic and diagnostic conditions. The solubilization protocol is simple, highly efficient, and results in a population of coated single-walled nanotubes which are highly stable.

The invention discloses a high-purity soya bean phosphatidyl choline without lysophosphatide preparing method in the phosphatide technique domain, which comprises the following steps: using soybean podwer phosphatide for raw material; extracting by dissolvant; freezing raffinate; treating liquor by dual column chromatogram; eluting for treating column 1; dislodging phosphatidyl ethanolamine; eluting and treating column2; dislodging lysophosphatide, wherein eluent of dissolvant,column 1 and column 2 for extracting is common single solvent; the production has no lysophosphatide; the bilineurine content of soya bean lecithin is more than 90%.

The invention provides a preparation method of instant yolk powder. The method comprises the following steps of: (a) mechanically dispersing yolk solution; (b) adding protease and phospholipase to the yolk solution, wherein the weight ratio of yolk solution to protease is 100:(0.1-0.5) and the weight measurement ratio of yolk solution to phospholipase is 100:(0.01-0.05); and (c) carrying out drying treatment. The preparation method has the beneficial effects that the proteins are appropriately hydrolyzed to micromolecules with different chain lengths by adding the protease and simultaneously the phospholipase is added to appropriately hydrolyze phospholipid in the yolk solution to generate lysophospholipid; and through synergy among enzyme preparations, such function properties of the hydrolysate as solubility, emulsibility and heat resistance are more obvious.

A method is disclosed for the generation of triacylglycerols from gums that have been separated from an oil product. The gums are treated with an enzyme having PLC activity, which results in the formation of diacylglycerols and phosphates, and treated with an enzyme having PLA activity, which results in the formation of lyso-phospholipids and free fatty acids. The diacylglycerols and the free fatty acids from these two separate reactions then combine in the presence of the enzymes to generate new triacylglycerol molecules.

A cloned of a human brain lysophospholipid-specific lysophospholipase enzyme molecule, its potential use for treatment of a host of diseases and method of inactivation are disclosed. Also disclosed are its distribution in tissue sand detailed kinetic analysis. hLysoPLA has a single substrate binding site and a surface recognition site. In contrast to many nonspecific lipolytic enzymes that exhibit lysophospholipase activity, hLysoPLA hydrolyzes only lysophospholipids and has no other significant enzymatic activity.

The invention relates to a thermosensitive liposome, which contains at least one phosphatidylcholine, at least one lysophospholipid, and at least one unsaturated phospholipid. The phase temperature of the liposome is 39.0DEG C-45.0DEG C. The liposome further contains a material having a long circulating characteristic and a fat-soluble active agent. Specifically, the phosphatidylcholine, the lysophospholipid, the unsaturated phospholipid, and the material having a long cycle characteristic are in a weight ratio of 69-94:1-6:1-10:4-15. And all the phospholipids and the fat-soluble active agent are in a weight ratio of 30-120:1-10. The invention also relates to a pharmaceutical composition containing the thermosensitive liposome. The invention additionally relates to application of the thermosensitive liposome and the pharmaceutical composition in preparing drugs treating tumors.

A composition and method for controlling diseases and pests on plants is provided. Specifically, the composition provides that polar glycerides selected from the group comprising monoglycerides, diglycerides, phospholipids, lysophospholipids, glycolipids, lysoglycolipids, or their derivatives control certain diseases or insect pests on plants.

The invention belongs to the technical field of gene engineering of enzymes, and discloses a preparation method of high-purity glycerophosphodiesters, which comprises the following steps: hydrolyzing lysophosphatide in a water phase system by taking lysophosphatide as a raw material and pfGDPD treated by a metal ion chelating agent as a catalyst to obtain a glycerophosphodiester product; the amino acid sequence of the pfGDPD is shown as SEQ ID No: 1. Starting from lysophospholipid, high-purity glycerophosphodiesters (such as GPC, GPE, GPI and the like) can be prepared through one step of hydrolysis by a single enzyme method, and the conversion rate is close to 100%. The invention provides a new thought and method for the production of glycerophosphate diester.

The invention discloses an EPA/DHA type lysophospholipid composition and a preparation method thereof, the composition comprises the following components: less than or equal to 25% of phospholipid PC,more than or equal to 65% of lysophospholipid LPC, and less than or equal to 10% of glycerocholine phosphate GPC, and the content of EPA/DHA in the lysophospholipid LPC is greater than 60%. The method comprises the following steps: taking phospholipid in the krill oil as a raw material, taking phospholipase A1 as a catalyst to catalyze an alcoholysis reaction of the phospholipid, ending the reaction when 80% of phospholipid substances in the krill oil are subjected to the alcoholysis reaction, adding cold acetone, performing standing or centrifuging, and taking a lower-layer phospholipid mixture; taking a phospholipid mixture obtained in the step 1 as a raw material, taking immobilized partial glyceride lipase as a catalyst, catalyzing the reaction of a byproduct GPC in the phospholipid mixture obtained in the step 1 with EPA/DHA and ester derivatives thereof, after the reaction is finished, adding cold acetone, performing standing or centrifuging, and taking the lower-layer phospholipid mixture, thereby obtaining the composition taking EPA/DHA lysophospholipid as a main component. The composition provided by the invention is rich in EPA/DHA type lysophospholipid and has an important health-care function.

The invention discloses an elemene injection. One liter of the injection consists of the following raw materials: 5 to 20 grams of elemene, 15 to 60 grams of soybean lecithin for injection, 5 to 99.9 grams of oil for injection, 12 to 30 grams of glycerol for injection, and the balance of phosphate buffer solution. The invention also discloses a method for preparing the elemene injection. By controlling the content of lysophosphatide in an auxiliary material, namely soybean lecithin, and key preparation process conditions, an anti-cancer medicament, namely the elemene injection, is prepared, which has no hemoclasis, no vascular irritation and no risk of the survival of microorganisms after the sterilization, is suitable for intravenous injection or arterial intervention, has a dosage form of medicament-loaded emulsions, and is safe and effective.